EGF Receptor / EGFR Antibody-L858R Mutant Specific

Immunohistochemistry (FFPE): 1-2ug/ml for 30 minutes at RT

Optimal dilution of the recombinant EGFR antibody should be determined by the researcher.

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Plays a role in enhancing learning and memory performance (By similarity). The epitope for this antibody is specifically expressed on EGFR-L858R mutated lung cancer.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide

A portion of amino acids 800-900 of EGF receptor (mutated L858R) was used as the immunogen for the recombinant EGFR antibody.

This recombinant EGFR antibody is available for research use only.

Cytomembrane

Protein A affinity chromatography

Human

P00533